Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
GLP-1 Drugs and Lumbar Fusion Surgery
A new meta-analysis found no significant link between GLP-1 drugs like semaglutide and complications after lumbar fusion surgery.
GLP-1 Drugs in Teens: The Nutrition Gap
A pediatric claims study finds nutritional deficiencies in teens on semaglutide and similar GLP-1 drugs, with most never referred for nutrition counseling.
Oral Semaglutide and Cardiovascular Risk
A new observational study links oral semaglutide to fewer heart attacks and strokes than other diabetes drugs.
Retatrutide, Prader-Willi and 100 kg Lost
A Prader-Willi syndrome case report describes 108.7 kg lost over 18 months on retatrutide, then oral semaglutide and dulaglutide.
Semaglutide for antipsychotic weight gain
A Danish feasibility trial will test weekly semaglutide in teens with antipsychotic-related obesity.
Semaglutide and Heart Risk in HIV
A new randomized trial found semaglutide improved calculated heart-disease risk and inflammation markers in adults with HIV, but not artery stiffness.
Semaglutide After Pancreatitis: A Case
A new case report describes semaglutide controlling refractory hypertriglyceridemia after six pancreatitis episodes.
Semaglutide and Limb Events: What We Know
A new editorial asks whether semaglutide's cardiovascular benefit now extends to limb outcomes in peripheral artery disease.
Semaglutide and Postmenopausal Bleeding
A new case report ties semaglutide to postmenopausal bleeding, but proving cause and effect from one patient is another matter.
How a Gila Monster Shaped GLP-1 Drugs
Exendin-4 from Gila monster venom helped open the path to exenatide. Here is how that finding relates to later GLP-1 medicines.
GLP-1 drugs and antipsychotic care
A 2026 meta-analysis pooled eight trials of GLP-1 receptor agonists for cardiometabolic outcomes in antipsychotic-treated patients.
GLP-1 and pulmonary hypertension
A new review finds mechanistic and preclinical signals for GLP-1 medicines in pulmonary hypertension, but no established clinical efficacy.